Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Here are some stocks to watch on Wednesday: ...

Investing.com - Abbott Laboratories (NYSE:ABT) has backed its full-year financial guidance despite noting a period of ...

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.

In a world where diabetes management is evolving at a rapid pace, the spotlight shines on non-invasive glucose monitors that ...

Another option is a continuous glucose monitor that is inserted into your arm or abdomen. Monitors approved by the Food and Drug Administration (FDA) include: Some people are able to control their ...